Brekiya® (dihydroergotamine) – New drug approval
May 15, 2025 - Amneal Pharmaceuticals announced the FDA approval of Brekiya (dihydroergotamine), for the acute treatment of migraine with or without aura and the acute treatment of cluster headaches in adults.
Download PDF
